GOLIMUMAB AS FIRST, SECOND OR AT LEAST THIRD BIOLOGIC AGENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) OR ANKYLOSING SPONDYLITIS (AS) - POST HOC ANALYSIS OF A NON-INTERVENTIONAL STUDY IN GERMANY

被引：0
|
作者：
Krueger, Klaus
Burmester, Gerd Ruediger [1 ]
Wassenberg, Siegfried [2 ]
Thiele, Astrid [3 ]
Thomas, Matthias [4 ]
机构：
[1] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[2] Rheumazentrum Ratingen, Ratingen, Germany
[3] St Josefs Hosp, Wuppertal, Germany
[4] MSD Sharp & Dohme GmbH, Med Affairs, Haar, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0166
引用
收藏
页码：1156 / 1157
页数：2
相关论文
共 50 条
  • [21] SOCIOECONOMIC ANALYSIS OF GOLIMUMAB TREATMENT IN PATIENTS WITH RA, PSA, AND AS - NON-INTERVENTIONAL STUDY GO-NICE
    Krueger, Klaus
    Burmester, Gerd Ruediger
    Wassenberg, Siegfried
    Thiele, Astrid
    Thomas, Matthias
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 622 - 623
  • [22] Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors
    Kathleen Tymms
    Geoff Littlejohn
    Hedley Griffiths
    Julien de Jager
    Paul Bird
    Fred Joshua
    Peter Nash
    Malcolm Handel
    Hamish McManus
    Belinda E. Butcher
    Peter Youssef
    Clinical Rheumatology, 2018, 37 : 1617 - 1623
  • [23] Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors
    Tymms, Kathleen
    Littlejohn, Geoff
    Griffiths, Hedley
    de Jager, Julien
    Bird, Paul
    Joshua, Fred
    Nash, Peter
    Handel, Malcolm
    McManus, Hamish
    Butcher, Belinda E.
    Youssef, Peter
    CLINICAL RHEUMATOLOGY, 2018, 37 (06) : 1617 - 1623
  • [24] Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as - Analysis of a Non-Interventional Study in Germany
    Krueger, Klaus
    Burmester, Gerd
    Wassenberg, Siegfried
    Thiele, Astrid
    Thomas, Matthias
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [25] Effectiveness and safety of adalimumab (humiha) therapy after failure of prior TNF-antagonists in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS)
    Burmester, G. R.
    Rudwaleit, M.
    Smith, V.
    Kary, S.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 64 - 65
  • [26] TREATMENT PATTERNS AMONG PATIENTS WITH RHEUMATIC DISEASE (RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA)) TREATED WITH SUBCUTANEOUS TNF-ALPHA ANTAGONISTS
    Tymms, K.
    Littlejohn, G.
    Griffiths, H.
    De Jager, J.
    Bird, P.
    Joshua, F.
    Nash, P.
    Handel, M.
    McManus, H.
    Butcher, B.
    Youssef, P.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 33 - 33
  • [27] GOLIMUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIASIS ARTHRITIS (PSA) AND AXIAL SPONDYLOARTHRITIS (AXSPA): INTERIM RESULTS FROM A NON-INTERVENTIONAL STUDY IN AUSTRIA (GO ACTIVE)
    Dejacol, C.
    Mueller, T.
    Zamani, O.
    Kurtz, U.
    Egger, S.
    Resch-Passini, J.
    Totzauer, A.
    Eisterer, W.
    Yazdani-Biuki, B.
    Schwingenschloegl, T.
    Peichl, P.
    Kraus, A.
    Naerr, G. W.
    Rickert, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 598 - 599
  • [28] USTEKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS - RESULTS OF THE FIRST INTERIM ANALYSIS OF THE NON-INTERVENTIONAL STUDY SUSTAIN
    Wendler, J.
    Schwarze, I.
    Schwenke, H.
    Behrens, J.
    Gruppe, T.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1322 - 1322
  • [29] Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study
    N. El Ouardi
    A. El Maghraoui
    H. J. Djossou
    L. Taoubane
    A. M. Ghassem
    H. Toufik
    A. Majjad
    S. Sadni
    A. Mounach
    I. Hmamouchi
    R. Abouqal
    R. Bahiri
    F. Allali
    I. El Bouchti
    I. Ghozlani
    H. Hassikou
    T. Harzy
    L. Ichchou
    O. Mkinsi
    R. Niamane
    A. Bezza
    Rheumatology International, 2023, 43 : 79 - 87
  • [30] Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort study
    El Ouardi, N.
    El Maghraoui, A.
    Djossou, H. J.
    Taoubane, L.
    Ghassem, A. M.
    Toufik, H.
    Majjad, A.
    Sadni, S.
    Mounach, A.
    Hmamouchi, I
    Abouqal, R.
    Bahiri, R.
    Allali, F.
    El Bouchti, I
    Ghozlani, I
    Hassikou, H.
    Harzy, T.
    Ichchou, L.
    Mkinsi, O.
    Niamane, R.
    Bezza, A.
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (01) : 79 - 87
12345